Alnylam Pharmaceuticals
$219.72Change from previous close: −4.96%Absolute change: −$11.46
At a glance
- Revenue growth
- +65.19%
- 2025 vs 2024
- Net margin
- 8.4%
- 2024: -12.4%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 4,966 | 4,240 | 3,830 | 3,546 | — |
| Current assets | 4,051 | 3,295 | 2,983 | 2,692 | — |
| Cash and equivalents | 1,657 | 966 | 813 | 866 | — |
| Short-term investments | 1,251 | 1,728 | 1,627 | 1,326 | — |
| Receivables | 778 | 405 | 328 | 238 | — |
| Inventory | 82.7 | 78.5 | 89.1 | 129 | — |
| Net property, plant and equipment | 708 | 694 | 726 | 739 | — |
| Current liabilities | 1,466 | 1,186 | 968 | 768 | — |
| Accounts payable | 116 | 88.4 | 55.5 | 98.1 | — |
| Long-term debt | 1,008 | 1,025 | 1,021 | 1,017 | — |
| Total debt | 1,278 | 1,296 | 1,305 | 1,320 | — |
| Total liabilities | 4,177 | 4,173 | 4,051 | 3,705 | — |
| Total equity (incl. minority) | 789 | 67.1 | -221 | -158 | — |
| Retained earnings | -6,703 | -7,288 | -7,010 | -6,569 | — |